AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of “” from Analysts
Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $2.50 for the company and are predicting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 159 out of 265 based on the ratings given to related companies.
AEZS has been the topic of a number of analyst reports. Maxim Group set a $10.00 price objective on AEterna Zentaris and gave the stock a “buy” rating in a research note on Wednesday, February 1st. HC Wainwright dropped their price objective on AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Finally, Zacks Investment Research cut AEterna Zentaris from a “buy” rating to a “hold” rating in a research note on Wednesday, March 8th.
AEterna Zentaris (NASDAQ:AEZS) traded up 1.6457% during trading on Wednesday, reaching $0.8894. The company had a trading volume of 34,845 shares. The company’s market capitalization is $12.75 million. The company has a 50 day moving average price of $1.98 and a 200 day moving average price of $2.88. AEterna Zentaris has a 52-week low of $0.78 and a 52-week high of $5.59.
AEterna Zentaris (NASDAQ:AEZS) last announced its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.02. AEterna Zentaris had a negative return on equity of 213.27% and a negative net margin of 3,773.91%. The company had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.85 million. During the same quarter in the prior year, the business posted ($0.37) EPS. The business’s revenue was up 8.3% compared to the same quarter last year. On average, equities analysts forecast that AEterna Zentaris will post ($1.39) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/05/24/aeterna-zentaris-inc-aezs-receives-consensus-recommendation-of-from-analysts.html.
A hedge fund recently raised its stake in AEterna Zentaris stock. Morgan Stanley increased its position in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 9.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 33,725 shares of the biopharmaceutical company’s stock after buying an additional 2,800 shares during the period. Morgan Stanley’s holdings in AEterna Zentaris were worth $102,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.59% of the company’s stock.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.